- Policy
- Government on new coronavirus, “All hands on deck”
- by Kim, Jung-Ju Feb 3, 2020 06:22am
- The Korean government body reported the Cheongwadae of pan-government response plan on the 2019 novel coronavirus after monitoring the current status of the outbreak. Along with the plan, the government officials discussed of a plan evacuating Korean residents in Wuhan, China, and providing other humanitarian support for China. At th
- Policy
- Chong Kun Dang's CKD-306 is approved for phase I
- by Lee, Tak-Sun Feb 3, 2020 06:20am
- Chong Kun Dang is continuing to develop a combination of diabetes drug 'Duvie' and DPP-4 inhibitor 'Sitagliptin'. In 2016, Chong Kun Dang, a candidate for the development of a combination drug known through clinical approval of drug interactions, was recently approved for phase I clinical trials and is now in full swing. The Ministry of
- InterView
- 27 years in the HIRA, feeling worthwhile in public service
- by Lee, Hye-Kyung Feb 3, 2020 06:20am
- There is a problem that the HIRA and the NHIS, which have completed the relocation to Wonju Innovation City, are worried. It is about recruiting professional personnel such as doctors and pharmacists. In particular, The number of pharmacist recruitment is 72 of the HIRA and 35 people in the NHIS, but both institutions cannot failed to fill th
- Company
- Talks resume on listing SGLT2 inhibitor combination therapy
- by Eo, Yun-Ho Jan 31, 2020 06:36am
- “Until the spring seminar, the association will have an official statement and deliver it to the government.” The Korean Diabetes Association (KDA) started fine tuning their opinions about expanding reimbursement on combination therapy consisting of sodium-glucose transport protein 2 (SGLT2) inhibitor. On Jan. 30, KDA convened a pre
- Company
- Tae-han Kim, CEO of BioLogics will be reappointed
- by Lee, Seok-Jun Jan 31, 2020 06:36am
- Samsungbioepis will operate the system of two vice presidents, and Tae-han Kim, CEO of SamsungbioLogics has confirmed that it is four consecutive years. The two companies made such key positions on January 30. The figures reflect results from last year's performance. Seven people were promoted. Another vice president was appointed.
- Company
- Resumed supply of Terramycin delayed from Feb to July
- by Jung, Hye-Jin Jan 31, 2020 06:35am
- The supply resumption date of Pfizer Korea’s Terramycin ophthalmic ointment has been pushed back. On Jan. 28, Pfizer Korea notified distributors, pharmacies and hospitals that Terramycin supply would resume around July. Apparently, the delayed production schedule is pushing down the resumption date. In last November, the company has
- Policy
- Industry welcomes pricing benefit unchanged for IMD
- by Lee, Jeong-Hwan Jan 31, 2020 06:35am
- The Korean pharmaceutical industry is positively reacting to Ministry of Health and Welfare’s (MOHW) revised drug pricing system including the weighted pricing benefit for incrementally modified drug (IMD) as it would allow IMDs to remain as a cash cow generating finance for new drug R&D. Although they are regretful the weighted pricing
- Policy
- Besivo's reimbursement standards expanded
- by Kim, Jung-Ju Jan 31, 2020 06:35am
- If the patient progresses to liver cancer during treatment with Besifovir oral medications, the benefit is still acceptable. In the case of Ramosetron HCl oral medications, there will be no restriction on the duration of administration, up to 12 weeks. The Ministry of Health and Welfare was confirmed on 28th after hearing opinions by th
- Company
- Keytruda awaits Cancer Committee’s nod in February
- by Eo, Yun-Ho Jan 30, 2020 06:34am
- The pharmaceutical industry is keeping their eyes close to the Korean government and MSD’s tug-of-war over expanding reimbursement on immunotherapy Keytruda. The industry reported on Jan. 30, the Cancer Disease Deliberation Committee is scheduled to deliberate reimbursement on Keytruda’s five indications including first-line treatment
- Policy
- Cresemba, Pfizer Korea's antifungal drug, approved
- by Lee, Tak-Sun Jan 30, 2020 06:34am
- Pfizer Korea obtained the product license of the antifungal drug Cresemba (Isavuconazole Sulfate) in Korea. The drug is expected to have a lower mortality rate than Pfizer's Vfend. The Ministry of Food and Drug Safety approved on the 29th the sale of 'Cresemba capsule 100mg' and 'Cresemba injection 200mg' of Pfizer Korea. Cresemba i
